Physician profile
Thomas Eugene Hurst
NPI 1134576960
$967.19
in general payments reported to CMS, 2019-2025
13 companies · $158 in 2025
The $158 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $441 · 2023: $368 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $526.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $234.76 | 2022-2023 | Dexcom G6 Transmitter |
| Abbott Laboratories | $148.10 | 2022-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Beta Bionics, INC. | $139.12 | 2023 | Ilet Bionic Pancreas |
| Sequel Med Tech, LLC | $137.55 | 2025 | Twiist |
| Astrazeneca Pharmaceuticals Lp | $112.58 | 2022 | |
| Lilly USA, LLC | $52.57 | 2022-2023 | Trulicity, Humulin, Mounjaro |
| Novo Nordisk INC | $45.47 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.86 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.69 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.18 | 2022 | |
| Xeris Pharmaceuticals, INC. | $15.14 | 2023 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $14.47 | 2023 | |
| Amryt Pharma Holdings Ltd | $12.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Hurst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.